MLL will be the first European user of Illumina's new high-throughput sequencing platform, the NovaSeq.
The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.
Pfizer will become the first firm to customize IBM's Watson for Drug Development, combining its proprietary data with licensed and publicly available data.
De-identified data from the study, which will look at 10,000 samples by whole-exome sequencing, will be made available for general research use.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The partnership provides oncology sequencing and cognitive analytics, and it offers a framework for employing Watson to explore a broader set of diagnostic opportunities.
The service provides broad access to information that may be critical for physicians in providing precision cancer treatments.
IBM is to make its Watson technology available to its employees to identify what cancer treatments might work for them, the Wall Street Journal reports.
Results from the Rheumatoid Arthritis Responder Dream Challenge did not support the use of common SNP data to improve treatment response prediction models.
The hospitals plan to use the Watson technology to help their clinicians personalize cancer treatment options for their patients.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligences for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.